Rafferty Asset Management’s Harmony Biosciences HRMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$258K Buy
6,574
+976
+17% +$37.7K ﹤0.01% 1033
2026
Q2
$204K Buy
+5,598
New +$177K ﹤0.01% 1104
2026
Q1
– Sell
-5,954
Closed -$223K – 1102
2025
Q4
$223K Buy
+5,954
New +$196K ﹤0.01% 1073
2025
Q2
– Sell
-7,545
Closed -$250K – 1090
2025
Q1
$250K Sell
7,545
-560
-7% -$20.1K ﹤0.01% 999
2024
Q4
$279K Buy
+8,105
New +$278K ﹤0.01% 1039
2024
Q1
– Sell
-7,374
Closed -$238K – 1087
2023
Q4
$238K Buy
+7,374
New +$206K ﹤0.01% 1046
2022
Q4
– Sell
-5,223
Closed -$231K – 1133
2022
Q3
$231K Buy
5,223
+26
+0.5% +$1.27K ﹤0.01% 1066
2022
Q2
$253K Buy
+5,197
New +$234K ﹤0.01% 978
2022
Q1
– Sell
-6,585
Closed -$281K – 1266
2021
Q4
$281K Buy
+6,585
New +$262K ﹤0.01% 1160

Other funds holding HRMY

Rafferty Asset Management's HRMY Position: Q3 2026 in Review

Rafferty Asset Management increased its Harmony Biosciences (HRMY) stake by 17% in Q3 2026, buying an estimated $37.7K and bringing the position to 6,574 shares worth $258K. The position accounts for ﹤0.01% of the portfolio, ranked #1033.

Rafferty Asset Management first reported a position in HRMY in Q4 2021 and has held it in 9 quarters since. The position peaked at $281K in Q4 2021. 358 funds tracked by Wall St. Rank hold HRMY as of Q3 2026.

  • Rafferty Asset Management held 6,574 shares of Harmony Biosciences worth $258K as of Q3 2026.
  • Rafferty Asset Management bought 976 Harmony Biosciences shares in Q3 2026, an estimated $37.7K.
  • Harmony Biosciences made up ﹤0.01% of Rafferty Asset Management's portfolio in Q3 2026, its #1033 holding.
  • Rafferty Asset Management first reported a position in Harmony Biosciences in Q4 2021 and has held it in 9 quarters since.
  • Rafferty Asset Management's Harmony Biosciences position peaked at $281K in Q4 2021.
  • 358 funds tracked by Wall St. Rank held Harmony Biosciences as of Q3 2026.

Based on Rafferty Asset Management's 13F filing for Q3 2026, filed 13 Nov 2026.